Cargando…
Design of Oral Sustained-Release Pellets by Modeling and Simulation Approach to Improve Compliance for Repurposing Sobrerol
Sobrerol, an oral mucolytic agent, in a recent study showed promise for treating multiple sclerosis. A human equivalent dose of 486 mg of sobrerol administered thrice daily (i.e., 1459 mg of daily dose) demonstrated the highest therapeutic efficacy for repurposing use, which also points out the poor...
Autores principales: | Lu, Chu-Hsun, Huang, Yu-Feng, Chu, I-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777650/ https://www.ncbi.nlm.nih.gov/pubmed/35057064 http://dx.doi.org/10.3390/pharmaceutics14010167 |
Ejemplares similares
-
Sobrerol: New Perspectives to Manage Patients with Frequent Respiratory Infections
por: Ciprandi, Giorgio, et al.
Publicado: (2023) -
Fenofibrate modified-release pellets with lag phase and high oral bioavailability
por: Li, Fang, et al.
Publicado: (2018) -
Preparation and pharmacokinetics in beagle dogs of ganershu sustained-release pellets
por: Pan, Jin-huo, et al.
Publicado: (2014) -
Analgesia Effect of Enteric Sustained-Release Tetrodotoxin Pellets in the Rat
por: Hong, Bihong, et al.
Publicado: (2020) -
Design of sustained release pellets of ferrous fumarate using cow ghee as hot-melt coating agent
por: Sakarkar, Dinesh M, et al.
Publicado: (2013)